Benjamin A. Olenchock

机构：Regeneron (United States) · ORCID：0000-0002-8956-5117

发表论文 81 篇 · 总被引 9472 次 · h-index 25

代表论文

• Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis (2025 · Journal of Hepatology · 被引 29)
• Preclinical, randomized phase 1, and compassionate use evaluation of REGN4461, a leptin receptor agonist antibody for leptin deficiency (2023 · Science Translational Medicine · 被引 21)
• Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials (2025 · The Lancet · 被引 15)
• MYC overrides HIF-1α to regulate proliferating primary cell metabolism in hypoxia (2023 · eLife · 被引 15)
• Diverse NKT cells regulate early inflammation and neurological outcomes after cardiac arrest and resuscitation (2024 · Science Translational Medicine · 被引 14)
• Targeted proteomic profiling of cardiogenic shock in the cardiac intensive care unit (2024 · European Heart Journal Acute Cardiovascular Care · 被引 8)